Welcome to our dedicated page for Neuroone Med Technologies SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a medical technology issuer focused on minimally invasive, high-definition EEG, ablation, drug delivery and brain stimulation solutions for neurological disorders, NeuroOne uses its SEC reports to present detailed information on its financial condition, operations, risks and material events.
Here you can review NeuroOne’s current reports on Form 8-K, which the company uses to announce events such as quarterly and annual financial results, preliminary revenue figures, FDA 510(k) clearances for devices like the OneRF Trigeminal Nerve Ablation System, capital raising activities and notices related to Nasdaq listing requirements. These filings often incorporate or reference press releases that describe product performance, regulatory milestones and developments in programs including the OneRF Ablation System, spinal cord stimulation initiatives and sEEG-based drug delivery.
In addition to 8-Ks, investors can consult NeuroOne’s periodic reports on Forms 10-Q and 10-K (when available) for comprehensive financial statements, management’s discussion and analysis, and risk factor disclosures tied to its neuromodulation and surgical appliance business. The company has also filed updates related to its at-the-market offering program, distribution agreements and other capital markets activities, which are documented in its SEC submissions.
Stock Titan enhances these NMTC filings with AI-powered summaries that highlight key points, such as revenue trends, gross margin changes, cash position commentary, regulatory updates and listing compliance discussions. Users can quickly identify items like FDA clearance announcements, preliminary annual revenue disclosures and Nasdaq minimum bid price notices, then drill into the full documents for deeper analysis. This page is designed to help investors, analysts and other interested readers efficiently navigate NeuroOne’s official SEC record.
NeuroOne Medical Technologies Corporation is asking stockholders to vote at its April 3, 2026 annual meeting on key governance and capital-structure items. Routine matters include electing two Class III directors, ratifying Baker Tilly US, LLP as auditor, and amending the 2025 Equity Incentive Plan.
The most significant proposal would authorize the Board to implement a reverse stock split at a ratio between 1-for-2 and 1-for-15 any time within one year, primarily to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The split would reduce outstanding shares but leave authorized shares unchanged, increasing the number of authorized, unissued shares.
The equity plan amendment would add 1,500,000 shares to the 2025 Equity Incentive Plan and introduce a five-year “evergreen” feature allowing annual increases of up to 5% of fully diluted shares from 2027 through 2031. Stockholders are also asked to approve the ability to adjourn the meeting to solicit more proxies if needed for the reverse split proposal.
NEUROONE MEDICAL TECHNOLOGIES Corp’s Chief Business Officer, David J. Wambeke, reported acquiring both stock options and common shares. On March 1, 2026, he received an option to purchase 500,000 shares of common stock at an exercise price of $0.00 per share. According to the terms, 25% of this option will vest on March 1, 2027, with the remaining 75% vesting in 12 equal quarterly installments starting March 31, 2027. On the same date, he also made an open-market purchase of 1,000,000 shares of common stock at a price of $0.6704 per share, bringing his directly owned common stock position to 1,000,000 shares.
NEUROONE MEDICAL TECHNOLOGIES Corp executive David J. Wambeke, the company’s Chief Business Officer, filed an initial Form 3 reporting his beneficial ownership in the company. The filing does not list any insider buy or sell transactions; it simply establishes his status as a reporting officer.
NeuroOne Medical Technologies Corporation is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held April 3, 2026 at its Eden Prairie, MN offices. Stockholders will vote to elect two Class III directors, ratify Baker Tilly as auditor, approve a Board-authorized reverse stock split (a 1-for-2 to 1-for-15 range), approve an amendment to the 2025 Equity Incentive Plan, and authorize adjournments to solicit additional proxies.
The record date for voting is February 20, 2026; 50,693,017 shares of Common Stock were outstanding as of that date. The Board may select the final reverse-split ratio and timing if stockholders approve the range.
NeuroOne Medical Technologies Corporation set April 3, 2026 as the date for its 2026 annual meeting of stockholders. The company will provide the exact time, location, and voting items in a future proxy statement.
Because this date is more than 30 days later than the prior year’s meeting anniversary, stockholder proposals seeking inclusion in the 2026 proxy materials under Rule 14a-8 must be received at the company’s principal executive offices by March 4, 2026.
NEUROONE MEDICAL TECHNOLOGIES Corp Chief Technology Officer Steve Mertens reported a Form 4 transaction involving company common stock. On this date, 7,376 shares were disposed of at a price of $0.68 per share as a tax-withholding disposition rather than an open-market sale. Following this transaction, Mertens directly owned 153,047 shares of NEUROONE MEDICAL TECHNOLOGIES Corp common stock.
NeuroOne Medical Technologies Corp officer Mark Christianson reported a tax-related share disposition. On February 18, 2026, he disposed of 1,812 shares of common stock at $0.68 per share to cover tax withholding. Following this transaction, he directly owns 228,920 common shares of the company.
NEUROONE MEDICAL TECHNOLOGIES Corp CEO and President David A. Rosa reported a Form 4 transaction involving company common stock. On February 18, 2026, he disposed of 71,325 shares at $0.68 per share in a tax-withholding disposition related to equity compensation, not an open-market sale. After this transaction, he directly owned 1,082,590 common shares.